Joe Barton actually said...

It looks to me like we have two issues here. We have an FDA issue, you are right, seeing Ms. Woodcock.

I cannot overstate the importance of treating each biosimilar individually rather than as if they were a generic drug.

We all agree that it is important for FDA to get it right, but most of us think it is also time for FDA to get on down the road.

I wish that Congresswoman Eshoo was a member of the subcommittee because, while I know a little bit about this, Anna is really the expert on...